Related Experiment Video
Updated: Apr 11, 2026

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells
Published on: November 21, 2025
Retinoic Acid Receptor Responder Protein 1 Promotes Tubular Fibrosis via the KH RNA Binding Domain Containing, Signal
Lin Ye1, Zhuoyuan Jiang1, Yong Wu1
1Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.
Key Points:
Retinoic acid receptor responder protein 1 is upregulated in proximal tubular epithelial cells in CKD. Soluble retinoic acid receptor responder protein 1 drives fibrosis by binding KH RNA binding domain containing, signal transduction associated 1, recruiting steroid receptor coactivator kinase, and inducing signal transducer and activator of transcription 3 phosphorylation.
Background:
Kidney fibrosis is a hallmark of CKD, yet its underlying mechanisms remain incompletely understood. Retinoic acid receptor responder protein 1 (RARRES1) is largely restricted to podocytes in healthy kidneys but was upregulated within the tubulointerstitium in CKD. However, its functional contribution to kidney fibrosis remains unclear.
Methods:
To assess the link between tubulointerstitial RARRES1 expression, eGFR, and fibrosis severity in patients with CKD, we analyzed multiple clinical datasets. RARRES1 upregulation in proximal tubular epithelial cells was confirmed in human CKD samples by immunofluorescence and RNAscope assays. Kidney fibrosis was evaluated in proximal tubule-specific Rarres1 knockout mice and RARRES1-overexpressing mice after CKD induction, including unilateral ureteral obstruction and folic acid-induced nephropathy. Mechanistically, mass spectrometry and coimmunoprecipitation, combined with truncation mutants, uncovered interactions among soluble RARRES1, KH RNA binding domain containing, signal transduction associated 1 (KHDRBS1), steroid receptor coactivator (Src) kinase, and phosphorylated signal transducer and activator of transcription 3 (STAT3). Pharmacologic blockade of STAT3 or Src kinase was used to evaluate the reversal of RARRES1-induced fibrotic phenotype.
Results:
Multiple datasets revealed that tubulointerstitial RARRES1 expression correlated with decreased eGFR and increased fibrosis severity in patients with CKD. Immunofluorescence and RNAscope confirmed RARRES1 upregulation specifically in proximal tubular epithelial cells in CKD. Proximal tubule-specific knockout of Rarres1 significantly attenuated kidney fibrosis in two independent CKD models. Conversely, RARRES1-overexpressing mice showed aggravated kidney fibrosis compared with controls in the unilateral ureteral obstruction model. Soluble RARRES1 was identified as the key pathogenic form, with its plasma levels correlating with declining kidney function in patients with CKD. Mechanistically, soluble RARRES1 bound KHDRBS1, recruited Src kinase, and induced STAT3 phosphorylation at Tyr705, leading to upregulation of profibrotic factors. Inhibition of STAT3 or Src kinase partially reversed the fibrotic phenotype induced by RARRES1 overexpression.
Conclusions:
Our findings demonstrated that RARRES1 played an important role in regulating kidney fibrosis through the KHDRBS1/Src/p-STAT3 signaling axis.
Insights
Retinoic acid receptor responder protein 1 (RARRES1) promotes kidney fibrosis in chronic kidney disease (CKD) by activating the KHDRBS1-Src-p-STAT3 pathway. Targeting this pathway may offer therapeutic strategies for kidney fibrosis.
Area of Science:
- Nephrology
- Molecular Biology
- Pathology
Background:
- Kidney fibrosis is a key feature of chronic kidney disease (CKD).
- The role of Retinoic acid receptor responder protein 1 (RARRES1) in kidney fibrosis is not well understood.
- RARRES1 is typically found in podocytes but is upregulated in the tubulointerstitium in CKD.
Purpose of the Study:
- To investigate the association between tubulointerstitial RARRES1 expression and kidney fibrosis severity in CKD patients.
- To elucidate the functional role and molecular mechanisms of RARRES1 in kidney fibrosis.
Main Methods:
- Analysis of clinical datasets correlating RARRES1 expression, eGFR, and fibrosis.
- Immunofluorescence and RNAscope assays to confirm RARRES1 upregulation in human CKD samples.
- Studies in proximal tubule-specific Rarres1 knockout and RARRES1-overexpressing mice.
- Mass spectrometry and co-immunoprecipitation to identify interacting proteins.
- Pharmacological inhibition of STAT3 and Src kinase.
Main Results:
- Tubulointerstitial RARRES1 expression correlated with reduced eGFR and increased fibrosis in CKD patients.
- RARRES1 knockout mice showed attenuated kidney fibrosis, while RARRES1 overexpression aggravated it.
- Soluble RARRES1 was identified as the pathogenic form, with plasma levels linked to kidney function decline.
- RARRES1 activates the KHDRBS1-Src-p-STAT3 pathway, increasing pro-fibrotic factors.
Conclusions:
- RARRES1 significantly contributes to kidney fibrosis development and progression.
- The KHDRBS1-Src-p-STAT3 signaling axis is a key mechanism by which RARRES1 promotes fibrosis.
- RARRES1 represents a potential therapeutic target for kidney fibrosis.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
Receptor Tyrosine Kinases
Abnormal Proliferation

